Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Depreciation & Amortization (CF) of $666000.0 for Q1 2026, up 6.05% year-over-year from $628000.0 in Q1 2025, and little changed quarter-over-quarter from $666000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $666000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $666000.0, up 6.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (up 6.59% YoY), and the FY2025 annual result was $2.6 million, up 6.83% from the prior year.
- Depreciation & Amortization (CF) steadied at $666000.0 in Q1 2026 per ARTV's latest filing, from $666000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $666000.0 in Q4 2025 and troughed at $500000.0 in Q2 2023.
- A 4-year average of $612000.0 and a median of $620500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 20.6% in 2024 and fell as far as 3.37% in 2024.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $594000.0 in 2023, then rose by 3.37% to $614000.0 in 2024, then climbed by 8.47% to $666000.0 in 2025, then changed by 0.0% to $666000.0 in 2026.
- Business Quant data shows ARTV's Depreciation & Amortization (CF) at $666000.0 in Q1 2026, $666000.0 in Q4 2025, and $662000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | 666,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 666,000.00 |
| Mar 31, 2026 | 666,000.00 |
| Dec 31, 2025 | 666,000.00 |
| Dec 31, 2025 | 666,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 628,000.00 |
| Mar 31, 2025 | 628,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Dec 31, 2023 | 594,000.00 |
| Dec 31, 2023 | 594,000.00 |